Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-19, Stock:NVS, The news for the past five days is as follows:
2018-12-12: NEWS1: J&J says its psoriasis drug superior to Novartis treatment in study.NEWS2: J&J says its psoriasis drug superior to Novartis' in study.
2018-12-13: NEWS1: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS2: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS3: J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study.NEWS4: Pre-Market Most Active for Dec 13, 2018 :  GE, LPL, KEP, NVS, ERIC, SQQQ, QD, PKX, AMD, MRNS, QQQ, TQQQ.NEWS5: Pre-Market Most Active for Dec 13, 2018 :  GE, LPL, KEP, NVS, ERIC, SQQQ, QD, PKX, AMD, MRNS, QQQ, TQQQ.NEWS6: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen.NEWS7: Novartis Reports EC Approval Of Xolair Syringe For Self-administration.NEWS8: Novartis Reports EC Approval Of Xolair Syringe For Self-administration.
2018-12-14: NEWS1: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS2: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS3: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS4: Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus.NEWS5: Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis.
2018-12-17: NEWS1: Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU.NEWS2: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS3: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS4: Incyte (INCY) Collaborates with Innovent for 3 Candidates.
2018-12-18: NEWS1: Tilray shares soar on deal with Novartis. Here's what it ....NEWS2: Why Tilray, Aphria, and Navistar International Jumped Today.NEWS3: Why Tilray, Aphria, and Navistar International Jumped Today.NEWS4: Stocks Pare Gains as Oil Plummets.NEWS5: Stocks Pare Gains as Oil Plummets.NEWS6: Close Update: Wall Street Propped Higher Amid Expectations for Dovish FOMC.NEWS7: Close Update: Wall Street Propped Higher Amid Expectations for Dovish FOMC.NEWS8: Health Care Sector Update for 12/18/2018: CBPO,TLRY,HQY,GLPG.NEWS9: Health Care Sector Update for 12/18/2018: CBPO,TLRY,HQY,GLPG.NEWS10: Tilray Jumps After Canadian Pot Stock Signs Deal With Novartis.NEWS11: What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL.NEWS12: What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL.NEWS13: Anji Licenses Regional Rights To Clinical Asset From Global Pharma.NEWS14: Anji Licenses Regional Rights To Clinical Asset From Global Pharma.NEWS15: TLRY Teams Up With Novartis, TLSA To Report Data In Q2, RARX Marches Ahead.NEWS16: TLRY Teams Up With Novartis, TLSA To Report Data In Q2, RARX Marches Ahead.NEWS17: Health Care Sector Update for 12/18/2018: TLRY,HQY,GLPG.NEWS18: Health Care Sector Update for 12/18/2018: TLRY,HQY,GLPG.NEWS19: Pfizer’s Stock Performance and Earnings Trends.NEWS20: Why Tilray Is Jumping Today.NEWS21: Why Tilray Is Jumping Today.NEWS22: What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL.NEWS23: Mid-Day Update: Stocks Turn Higher As Wall Street Sees Fed At End of Rate Hike Cycle.NEWS24: Mid-Day Update: Stocks Turn Higher As Wall Street Sees Fed At End of Rate Hike Cycle.NEWS25: Analyzing Pfizer’s Revenues in December.NEWS26: Why Tilray Is Jumping Today.NEWS27: Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug.NEWS28: Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug.NEWS29: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS30: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS31: Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer.NEWS32: Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer.NEWS33: Tilray Partners with Novartis in Big Pharma’s First Deal of Its Kind with Big Marijuana.NEWS34: Tilray Shares Surge on Novartis Distribution Deal.NEWS35: J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed.NEWS36: J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed.NEWS37: What Happened With CAR-T Stocks in 2018.NEWS38: What Happened With CAR-T Stocks in 2018.NEWS39: Tilray Shares Jump On The Back Of Novartis Partnership.NEWS40: Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer.NEWS41: Tilray partners with Novartis in Big Pharma’s first deal of its kind with Big Marijuana.NEWS42: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS43: Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug.NEWS44: Cannabis company Tilray shares jump 11% after announcing deal with Swiss drugmaker Novartis.NEWS45: Cannabis company Tilray shares jump 11% after announcing deal with Swiss drugmaker Novartis.NEWS46: J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed.NEWS47: Pre-Market Most Active for Dec 18, 2018 :  RCII, AEG, FLEX, SQQQ, NVS, AMD, QQQ, GE, UL, CFG, BHP, TQQQ.NEWS48: Pre-Market Most Active for Dec 18, 2018 :  RCII, AEG, FLEX, SQQQ, NVS, AMD, QQQ, GE, UL, CFG, BHP, TQQQ.NEWS49: Cannabis Company Tilray Inks Distribution Deal With Novartis, Shares Up 12%.NEWS50: Cannabis Company Tilray Inks Distribution Deal With Novartis, Shares Up 12%.NEWS51: Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU.NEWS52: Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU.

Answer: Decrease